Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Millennium will buy AnorMED
October 2, 2006
| A version of this story appeared in
Volume 84, Issue 40
Millennium Pharmaceuticals has announced an agreement to acquire AnorMED for $515 million, a price representing a 40% premium over the hostile bid for AnorMED made by Genzyme in August (C&EN, Sept. 4, page 23). Millennium's target in the acquisition is the Canadian firm's hematology-oncology therapy Mozobil, a small-molecule chemokine antagonist currently in Phase III clinical trials. Mozobil has been shown to mobilize bone marrow stem cells in myeloma and lymphoma patients undergoing transplantation. According to Millennium CEO Deborah Dunsire, it would complement her firm's Velcade, a myeloma drug codeveloped with Johnson & Johnson.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter